Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab vs Secukinumab in Moderate to Severe Chronic Plaque Psoriasis
NCT03536884Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2018
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of bimekizumab in psoriasis, sponsored by UCB. Started Jun 2018; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03536884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536884.